• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 3. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Ethyl 2-(4-Iodo-1H-Pyrazol-1-Yl)Propanoate: A Promising Chemical Entity in Modern Medicinal Chemistry

Among the diverse array of organic compounds studied in medicinal chemistry, Ethyl 2-(4-iodo-1H-pyrazol-1-yl)propanoate (CAS No. 1217862-33-3) has emerged as a critical intermediate in drug discovery programs targeting oncology and inflammatory disorders. This compound, characterized by its unique structural features including a substituted pyrazole ring and an iodoaryl moiety, represents a strategic design that balances pharmacokinetic properties with biological activity. Recent advancements in synthetic methodologies have enabled scalable production of this compound, positioning it as a key building block for next-generation therapeutics.

The core structure of Ethyl 2-(4-iodo-1H-pyrazol-1-yl)propanoate combines the pharmacophoric potential of the pyrazole scaffold with the tunable reactivity of an iodine substituent. Pyrazole derivatives have long been recognized for their ability to modulate protein kinases and transcription factors implicated in cancer progression. The presence of the iodo group at position 4 provides an ideal site for post-synthetic modification through palladium-catalyzed cross-coupling reactions, enabling precise functionalization to optimize target specificity. This structural flexibility was highlighted in a 2023 study published in Journal of Medicinal Chemistry, where researchers demonstrated how such modifications could enhance selectivity for bromodomain-containing proteins associated with epigenetic dysregulation.

In preclinical models, this compound has shown remarkable efficacy as a multitarget inhibitor across multiple disease pathways. A landmark study from Stanford University's Department of Chemical Biology revealed that when administered at submicromolar concentrations, the compound significantly inhibited NF-kB activation while simultaneously downregulating COX-2 expression in murine models of rheumatoid arthritis. The ethyl ester group proved crucial for achieving optimal bioavailability, maintaining plasma levels above therapeutic thresholds for over six hours post-administration. These findings underscore its potential as a dual-action agent capable of addressing both inflammatory processes and their underlying genetic drivers.

Synthetic strategies for this compound have evolved significantly since its initial characterization. Traditional methods involving Grignard reagents and azide chemistry have been supplanted by more efficient protocols utilizing microwave-assisted Suzuki-Miyaura coupling. A recent process optimization reported in Green Chemistry achieved 98% purity using recyclable catalyst systems and solvent-free conditions, reducing production costs by 40% compared to conventional methods. Such advancements align with current industry trends toward sustainable synthesis practices while maintaining strict adherence to ICH Q7 quality standards.

Clinical translation studies are currently underway at multiple institutions focusing on its application in immuno-oncology therapies. Preclinical data indicates synergistic effects when combined with checkpoint inhibitors, particularly in solid tumor models where it enhances T-cell infiltration into hypoxic tumor microenvironments. The iodo group's capacity for radiolabeling opens new avenues for positron emission tomography (PET) imaging applications, allowing real-time monitoring of drug distribution and receptor occupancy—a critical advancement for personalized medicine approaches.

Structural analysis using X-ray crystallography has revealed key hydrogen-bonding interactions between the pyrazole nitrogen atoms and conserved residues within kinase ATP-binding pockets. Molecular dynamics simulations conducted at ETH Zurich further validated its ability to induce conformational changes favoring allosteric inhibition mechanisms—a discovery that challenges traditional views on kinase inhibitor design paradigms. These insights are now being leveraged to create second-generation analogs with improved blood-brain barrier penetration properties.

In toxicological evaluations conducted under OECD guidelines, no significant hepatotoxicity or genotoxic effects were observed at therapeutic doses up to 50 mg/kg/day in rat models over 90-day exposure periods. The ethyl ester group's metabolic stability appears responsible for minimizing off-target effects compared to earlier carboxylic acid precursors studied during lead optimization phases.

This compound's unique profile positions it at the intersection of several rapidly evolving therapeutic areas: epigenetic therapy through bromodomain modulation; anti-inflammatory action via NF-kB pathway suppression; and targeted delivery systems enabled by its radiolabeling capacity. As next-generation sequencing technologies advance our understanding of disease heterogeneity, compounds like Ethyl 2-(4-Iodo...Propanoate will play pivotal roles in developing precision medicines tailored to individual patient biomarkers.

Ongoing collaborations between pharmaceutical companies and academic research groups are exploring its utility as a prodrug carrier system capable of delivering hydrophobic payloads across cellular membranes—a concept validated through recent studies demonstrating enhanced delivery efficiency when conjugated with siRNA molecules targeting KRAS mutations.

The integration of artificial intelligence-driven QSAR modeling into development pipelines has accelerated identification of optimal substituent patterns on the pyrazole core. Machine learning algorithms trained on datasets from >500 analogs successfully predicted novel substituent combinations that increased solubility by three orders of magnitude without compromising inhibitory activity—a breakthrough highlighted during the 2024 American Chemical Society National Meeting.

In conclusion, Ethyl 2-(4-Iodo...Propanoate exemplifies how strategic molecular design combined with cutting-edge synthetic techniques can address longstanding challenges in drug development. Its evolving role from laboratory intermediate to clinical candidate reflects contemporary trends prioritizing multifunctional agents capable of addressing complex disease mechanisms while meeting rigorous safety standards.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)